Akhil Chopra

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.2K citations · Full text

Hepatology, Medicine, Expansion Trial +9

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Wan‐Teck Lim, Boon Cher Goh, Edwin P. Hui et al. · Journal of Clinical Oncology · 2018 · 455 citations · Full text

Metastatic Npc, Oncology, Antitumor Activity +15

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim et al. · Journal of Hepatology · 2019 · 267 citations · Full text

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi et al. · Journal of Clinical Oncology · 2015 · 196 citations

Antitumor Activity, Immunology, Pharmacotherapy +20